Duocarmycin DM

• Description :

  Duocarmycin DM, a DNA minor-groove alkylator, is an antibody agent conjugates (ADCs) toxin. Duocarmycin DM is based on its characteristic curved indole structure and a spirocyclopropylcyclohexadienone electrophile to act anticancer activity[1][2].

• UNSPSC :

  12352203

• Target :

  ADC Payload; DNA Alkylator/Crosslinker

• Type :

  ADC Related

• Related Pathways :

  Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/duocarmycin-dm.html

• Purity :

  99.15

• Solubility :

  10 mM in DMSO

• Smiles :

  OC1=C2C(C=CC=C2)=C3C(N(C[C@H]3CCl)C(C4=CC5=C(N4)C=CC(OCCN(C)C)=C5)=O)=C1.OC(C(F)(F)F)=O

• Molecular Formula :

  C28H27ClF3N3O5

• Molecular Weight :

  577.98

• References & Citations :

  [1]Patil PC, et al. A Short Review on the Synthetic Strategies of Duocarmycin Analogs that are Powerful DNA Alkylating Agents. Anticancer Agents Med Chem. 2015;15 (5) :616-630.|[2]Koch MF, et al. Structural, Biochemical, and Computational Studies Reveal the Mechanism of Selective Aldehyde Dehydrogenase 1A1 Inhibition by Cytotoxic Duocarmycin Analogues. Angew Chem Int Ed Engl. 2015 Nov 9;54 (46) :13550-4.|[3]Chen KC, et al. Selective cancer therapy by extracellular activation of a highly potent glycosidic duocarmycin analogue. Mol Pharm. 2013;10 (5) :1773-1782.|[4]Tietze LF, Krewer B, von Hof JM, Frauendorf H, Schuberth I. Determination of the biological activity and structure activity relationships of drugs based on the highly cytotoxic duocarmycins and CC-1065. Toxins (Basel) . 2009;1 (2) :134-150. |[5]Tietze LF, Schuster HJ, Schmuck K, Schuberth I, Alves F. Duocarmycin-based prodrugs for cancer prodrug monotherapy. Bioorg Med Chem. 2008;16 (12) :6312-6318.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C (Powder, sealed storage, away from moisture)

• Scientific Category :

  ADC Related

• Clinical Information :

  No Development Reported

• Isoform :

  Daunorubicins/Doxorubicins